Candel Therapeutics Files 8-K: Material Agreement
Ticker: CADL · Form: 8-K · Filed: Jun 24, 2025 · CIK: 1841387
Sentiment: neutral
Topics: material-definitive-agreement, regulatory-filing
TL;DR
Candel Therapeutics just signed a big deal, filing an 8-K today.
AI Summary
On June 23, 2025, Candel Therapeutics, Inc. entered into a Material Definitive Agreement. The filing also includes Regulation FD Disclosure and Financial Statements and Exhibits. Candel Therapeutics, Inc. is incorporated in Delaware and its fiscal year ends on December 31.
Why It Matters
This filing indicates a significant new agreement for Candel Therapeutics, which could impact its business operations and future financial performance.
Risk Assessment
Risk Level: medium — Material Definitive Agreements can introduce new risks or opportunities that are not yet fully understood.
Key Players & Entities
- Candel Therapeutics, Inc. (company) — Registrant
- June 23, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 117 Kendrick St Suite 450 (address) — Principal Executive Offices
- Needham, Massachusetts (location) — Principal Executive Offices Location
- 02494 (zip_code) — Principal Executive Offices Zip Code
- (617) (phone_number) — Registrant's Telephone Number
FAQ
What type of Material Definitive Agreement did Candel Therapeutics, Inc. enter into?
The filing states that Candel Therapeutics, Inc. entered into a Material Definitive Agreement on June 23, 2025, but the specific details of the agreement are not provided in this excerpt.
What is the primary business of Candel Therapeutics, Inc.?
Candel Therapeutics, Inc. is in the business of Biological Products (No Diagnostic Substances), as indicated by its Standard Industrial Classification code [2836].
When is Candel Therapeutics, Inc.'s fiscal year end?
Candel Therapeutics, Inc.'s fiscal year ends on December 31.
Where are Candel Therapeutics, Inc.'s principal executive offices located?
The principal executive offices of Candel Therapeutics, Inc. are located at 117 Kendrick St Suite 450, Needham, Massachusetts, 02494.
What is the SEC file number for Candel Therapeutics, Inc.?
The SEC file number for Candel Therapeutics, Inc. is 001-40629.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 24, 2025 regarding Candel Therapeutics, Inc. (CADL).